Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
NCT02954094 · View on ClinicalTrials.gov ↗
Study Summary
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Conditions Studied
Study Locations (20)
California
- University of Southern California/Norris Comprehensive Cancer Center — Los Angeles
- Stanford University — Palo Alto
- California Liver Research Institute — Pasadena
- University of California-Davis — Sacramento
- University of California — San Francisco
Florida
- Gastro Florida — Clearwater
- University of Florida Hepatology Research at CTRB — Gainesville
- University of Florida Health Gastroenterology — Jacksonville
- Schiff Center for Liver Diseases/University of Miami — Miami
- Tampa General Medical Group — Tampa
Georgia
- Piedmont Atlanta Hospital — Atlanta
- Piedmont Cancer Institute — Atlanta
- Emory University Hospital — Atlanta
Illinois
- Northwestern University Division of Gastroenterology and Hepatology — Chicago
- Rush University Medical Center — Chicago
- University of Chicago — Chicago
Arizona
- Banner University Medical Center — Phoenix
Arkansas
- University of Arkansas — Little Rock
District of Columbia
- Georgetown University — Washington D.C.
Iowa
- University of Iowa Hospitals and Clinics — Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2016-12 |
| Est. Completion | 2027-02 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02954094
The ClinicalTrials.gov registry entry for NCT02954094 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Target PharmaSolutions, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Hepatocellular Cancer appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02954094 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, Florida, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02954094 about?
NCT02954094 is a clinical study titled "A Longitudinal Observational Study of the Natural History and Management of Patients With HCC". TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectru...
What is the current status of trial NCT02954094?
This trial is currently active not recruiting. The enrollment target is 10,000 participants. The study started on 2016-12. Estimated completion is 2027-02.
What conditions does trial NCT02954094 study?
This clinical trial studies the following conditions: Hepatocellular Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT02954094?
This trial is sponsored by Target PharmaSolutions, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02954094 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.